Mode
Text Size
Log in / Sign up
N/A N=34 Randomized Basic Science

Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)

Cigarette Smoking

Enrolled (actual)
34
Serious AEs
2.9%
Results posted
Nov 2018
Primary outcome: Primary: Change in Fagerstrom Test of Nicotine Dependence Score — .67; 1.33 score on a scale — p=0.39

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nicotine Patch (Drug); SPECTRUM Nicotine Research Cigarettes (0.07 mg) (Drug); MCE+ (Behavioral); MCE- (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Francis McClernon, Ph.D.
Primary completion
Sep 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Fagerstrom Test of Nicotine Dependence Score
.67; 1.33 0.39
PRIMARY
Number of Participants Who Met Relapse Criteria
9; 11
SECONDARY
Change From Baseline in Number of Usual Brand Cigarettes Smoked (EXT Engagement)
0; -1.32
SECONDARY
Change in Number of Cigarettes Smoked Per Day (EXT Response)
3.05; -.35
SECONDARY
Change in Craving Score During MCE Task (MCE Response)
14.58; 0.98; 11.88; 4.29; 8.25; 1.34
SECONDARY
Change in Post-quit Cue-reactivity
23.2; 15.2

Summary

The central objective of the project is to evaluate the effect of incorporating smoking related contexts into very low nicotine content (VLNC) cigarette extinction trials on clinically relevant, smoking-related outcomes. Adult smokers interested in quitting smoking (N=80) will be interviewed and trained to take pictures where they smoke cigarettes. Following taking these pictures, participants will then be switched to smoke VLNCs while wearing a 21 mg/d nicotine patch (EXT) for three weeks. During this 3-week treatment period, half of the sample (n=40) will be randomly assigned to undergo six, 60-minute sessions of multiple context extinction (MCE+) during which they will view smoking-related environments and smoke their assigned cigarettes. The remaining 40 participants will undergo control MCE (exposure to nature environments; MCE-) and smoke their assigned cigarettes. At the end of the three weeks, participants will quit smoking and continue to wear the nicotine patch while being followed during a 10-week abstinence period. Participants will also complete a follow-up phone call 6 months after their quit day.

Eligibility Criteria

Inclusion Criteria

  • generally healthy (i.e. ambulatory, not currently sick)
  • interest in quitting smoking
  • smoking of at least 5 cig/day of a brand delivering ≥ 0.5 mg nicotine (FTC method) for > 1 year
  • an expired carbon monoxide concentration of at least 10 ppm (to confirm inhalation) or urinary cotinine > 1000 ng/mL to confirm daily smoking (NicAlert=6)

Exclusion Criteria

  • inability to attend all required experimental sessions
  • desire to quit smoking prior to the study quit date
  • a quit attempt resulting in greater than 3 days of abstinence in the past 30 days
  • report of significant health problems including but not restricted to (e.g. chronic hypertension, emphysema, seizure disorder, history of significant heart problems)
  • unstable psychiatric conditions (any significant change in psychiatric symptoms during the past 3 months as determined by the study physician)
  • schizophrenia and schizoaffective disorder
  • psychiatric medication changes (e.g. new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms
  • use of other tobacco products or e-cigarettes more than 9 days in the past 30 days
  • current alcohol or drug abuse
  • use of illegal drugs (excluding marijuana) or drugs without a valid prescription as measured by urine drug screen
  • current use of nicotine replacement therapy or other smoking cessation treatment
  • use of Theophylline for asthma
  • presence of conditions contraindicated for nicotine replacement therapy (e.g., skin allergies)
  • previous participation in a study within the past year involving use of Spectrum cigarettes
  • systolic BP greater than or equal to 140 (participants failing for blood pressure will be allowed to rescreen once)
  • diastolic BP greater than or equal to 90 (participants failing for blood pressure will be allowed to rescreen once)
  • heart rate greater than or equal to 100 (participants failing for heart rate will be allowed to rescreen once)
  • blood alcohol level >0.0 (participants failing the blood alcohol screen will be allowed to rescreen once)
  • pregnant, trying to become pregnant, or breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02538042). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search